Wuhan YZY Biopharma Co., Ltd. Class H ( ($HK:2496) ) has issued an update. Wuhan YZY Biopharma has received Investigational New Drug approval from ...

Hemlibra (emicizumab) is a brand-name drug that’s prescribed to prevent bleeding episodes due to hemophilia A in adults and children. Hemlibra comes as a subcutaneous injection that’s given once per ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary analysis of the Phase III HAVEN 7 study reinforced ...

– There is limited information and treatment guidance on moderate and mild hemophilia A, which can lead to delayed or missed diagnoses of bleeding episodes – – Hemlibra is approved to treat people of ...

TOKYO--(BUSINESS WIRE)-- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai Pharma Taiwan Ltd., a wholly owned subsidiary of Chugai, launched Hemlibra®, a new drug created by ...

For people with the bleeding disorder hemophilia, the smallest bump, bruise, or cut can develop into a major health risk. Those living with hemophilia often spend their days with an ever-present ...

Basel, 19 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the phase IIIb STASEY study, which confirm the favourable safety profile of Hemlibra® ...

Aug 7 (Reuters) - Roche Holding AG: * HOFFMANN-LA ROCHE LIMITED - HEALTH CANADA HAS APPROVED HEMLIBRA (EMICIZUMAB INJECTION) FOR HEMOPHILIA A (CONGENITAL FACTOR VIII DEFICIENCY) PATIENTS Source text ...

JW Pharmaceutical said on the 20th that hemophilia A treatment Hemlibra (ingredient name emicizumab) has been newly added to the World Health Organization (WHO) Model List of Essential Medicines and ...

JW Pharmaceutical said Sunday that it had gained the South Korean drug regulator’s nod to begin domestic sales of the hemophilia treatment Hemlibra, developed by Chugai, a Roche-owned company. JW ...